BMRB Entry 18741

Assembly:

Entities:

Entity 1, FGFR1 kinase 334 residues - 38202 Da.

Sequence used here for human FGFR1 kinase domain (residues 455-765), contains a mutated catalytic Asp (D623A) plus two additional mutations designed to improve stability (C488A and C584S)

Samples:

sample_1: FGFR1, [U-13C; U-15N; U-2H], 0.45 ± 0.05 mM; sodium phosphate 50 mM; DTT 2 mM; EDTA 0.1 mM; sodium azide 0.02%; D2O 5%

sample_2: FGFR1, [U-15N, U-50% 2H], 0.45 ± 0.05 mM; sodium phosphate 50 mM; DTT 2 mM; EDTA 0.1 mM; sodium azide 0.02%; D2O 5%

sample_3: FGFR1, [U-15N]-Leu, 0.05 mM; sodium phosphate 50 mM; DTT 2 mM; EDTA 0.1 mM; sodium azide 0.02%; D2O 5%

sample_4: FGFR1, [U-15N]-Thr, 0.05 mM; sodium phosphate 50 mM; DTT 2 mM; EDTA 0.1 mM; sodium azide 0.02%; D2O 5%

sample_5: FGFR1, [U-15N]-Val, 0.05 mM; sodium phosphate 50 mM; DTT 2 mM; EDTA 0.1 mM; sodium azide 0.02%; D2O 5%

sample_6: FGFR1, [U-15N]-Tyr, 0.05 mM; sodium phosphate 50 mM; DTT 2 mM; EDTA 0.1 mM; sodium azide 0.02%; D2O 5%

sample_7: FGFR1, [U-15N]-Met, 0.05 mM; sodium phosphate 50 mM; DTT 2 mM; EDTA 0.1 mM; sodium azide 0.02%; D2O 5%

sample_8: FGFR1, [U-15N]-Phe, 0.05 mM; sodium phosphate 50 mM; DTT 2 mM; EDTA 0.1 mM; sodium azide 0.02%; D2O 5%

sample_9: FGFR1, [U-15N]-Ile, 0.05 mM; sodium phosphate 50 mM; DTT 2 mM; EDTA 0.1 mM; sodium azide 0.02%; D2O 5%

sample_conditions_1: ionic strength: 50 mM; pH: 7.0; pressure: 1 atm; temperature: 298 K

Experiments:

Software:

TOPSPIN v2.1, Bruker Biospin - collection

CARA v1.8.4, Rochus Keller, Kurt Wuthrich - chemical shift assignment

NMRPipe, Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax - processing

NMR spectrometers:

• Bruker Avance 800 MHz
• Bruker Avance 800 MHz
• Bruker Avance 800 MHz
• Bruker Avance 800 MHz